Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Up 136.0% in December

Aadi Bioscience, Inc. (NASDAQ:AADI) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totalling 547,500 shares, an increase of 136.0% from the December 15th total of 232,000 shares. Based on an average trading volume of 322,600 shares, the short-interest ratio is currently 1.7 days. Approximately 2.7% of the shares of the company are short sold.

Aadi Bioscience Price Performance

Aadi Bioscience stock opened at $3.02 on Tuesday. The firm has a market capitalization of $74.43 million, a P/E ratio of -1.32 and a beta of 0.65. Aadi Bioscience has a one year low of $1.21 and a one year high of $3.81. The business has a fifty day moving average price of $2.61 and a 200-day moving average price of $2.03.

Aadi Bioscience (NASDAQ:AADI) last issued its earnings results on Wednesday, November 6th. The company reported ($0.46) EPS for the quarter, hitting the consensus estimate of ($0.46). Aadi Bioscience had a negative return on equity of 71.87% and a negative net margin of 246.06%. The business had revenue of $7.21 million during the quarter, compared to the consensus estimate of $6.55 million. During the same quarter last year, the company earned ($0.60) EPS. Sell-side analysts expect that Aadi Bioscience will post -1.78 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aadi Bioscience

Several hedge funds have recently bought and sold shares of the company. XTX Topco Ltd purchased a new stake in Aadi Bioscience in the 3rd quarter worth approximately $32,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Aadi Bioscience in the second quarter worth $37,000. Finally, BML Capital Management LLC bought a new position in shares of Aadi Bioscience in the third quarter worth $4,120,000. Hedge funds and other institutional investors own 52.08% of the company’s stock.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.